Mounting evidence, including the recent (and unprecedented) phase 2 data on retatrutide, supports a role for incretin hormone agonists in treating obesity. But with great power comes great responsibility.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
What is the pipeline for future medications for obesity?
International Journal of Obesity Open Access 01 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jastreboff, A. M. et al. N. Engl. J. Med. 389, 514–526 (2023).
Rosenstock, J. et al. Lancet 402, S0140–6736 (2023).
Nogueiras, R., Nauck, M. A. & Tschöp, M. H. Nat. Metab. 5, 933–944 (2023).
Wilding, J. P. H. et al. N. Engl. J. Med. 384, 989–1002 (2021).
Davies, M. et al. Lancet 397, 971–984 (2021).
Jastreboff, A. M. et al. N. Engl. J. Med. 387, 205–216 (2022).
Garvey, W. T. et al. Lancet 402, 613–626 (2023).
Le Roux, C. Diabetes https://doi.org/10.2337/db23-51-OR (2023).
Wharton, S. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2302392 (2023).
Knop, F. K. et al. Lancet 402, 705–719 (2023).
Saxena, A. R. et al. JAMA Netw. Open. 6, e2314493 (2023).
Aroda, V. R. et al. Lancet 402, 693–704 (2023).
Frias, J. P. et al. Lancet 402, 720–730 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
I.L. received grants paid to the Institution from Novo Nordisk, Pfizer, Merck, Sanofi, Boehringer Ingelheim and Mylan; and received consulting fees and covered travel expenses from Novo Nordisk, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Sanofi, Boehringer Ingelheim, Zealand, Bayer, Intercept, Valeritas, Structure, Carmot, Shionoghi, Mediflix and WebMD.
Rights and permissions
About this article
Cite this article
Lingvay, I., Agarwal, S. A revolution in obesity treatment. Nat Med 29, 2406–2408 (2023). https://doi.org/10.1038/s41591-023-02538-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02538-7
This article is cited by
-
What is the pipeline for future medications for obesity?
International Journal of Obesity (2024)
-
Diabetes Technology in People with Type 2 Diabetes: Novel Indications
Current Diabetes Reports (2024)
-
Risk Stratification and Treatment of Obesity for Primary and Secondary Prevention of Cardiovascular Disease
Current Atherosclerosis Reports (2024)
-
Keeping the weight off
Nature Medicine (2023)